Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

[1]  G. Pellacani,et al.  A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[3]  B. Elewski,et al.  Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  L. Sawyer,et al.  The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis , 2018, The Journal of dermatological treatment.

[5]  M. Lebwohl,et al.  Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations , 2017, The British journal of dermatology.

[6]  M. Lebwohl,et al.  Rapid onset of action in patients with moderate‐to‐severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE‐2 and AMAGINE‐3) , 2017, Journal of the American Academy of Dermatology.

[7]  A. Armstrong,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA , 2017, Journal of the American Academy of Dermatology.

[8]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[9]  B. Strober,et al.  Clinical meaningfulness of complete skin clearance in psoriasis. , 2016, Journal of the American Academy of Dermatology.

[10]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[11]  S. Feldman,et al.  Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice , 2016, The Journal of dermatological treatment.

[12]  Jashin J. Wu,et al.  Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. , 2015, Journal of drugs in dermatology : JDD.

[13]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[14]  D. Revicki,et al.  Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis , 2015, The Journal of dermatological treatment.

[15]  A. Troxel,et al.  Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. , 2014, Journal of the American Academy of Dermatology.

[16]  K. Gordon,et al.  Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity , 2013, The Journal of dermatological treatment.

[17]  A. Gottlieb,et al.  Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity , 2013, The Journal of dermatological treatment.

[18]  A. Armstrong,et al.  Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011 , 2012, PloS one.

[19]  S. Feldman,et al.  Factors affecting sleep quality in patients with psoriasis. , 2010, Journal of the American Academy of Dermatology.

[20]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[21]  J. Saurat,et al.  Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis , 2008, Dermatology.

[22]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[23]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[24]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[25]  J. Nunnally,et al.  Psychometric Theory , 2020, Encyclopedia of Behavioral Medicine.

[26]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study , 2017, Journal of the American Academy of Dermatology.

[27]  V. Preedy,et al.  Dermatology Life Quality Index , 2010 .

[28]  R. Sitgreaves.  Psychometric theory (2nd ed.). , 1979 .